Drug treatment of prehypertension: Not now, not ever?

Blood Pressure

Volumn 18, Issue 6, 2009, Pages 304-307

  McInnes, Gordon T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular risk; Cost effectiveness; Pharmacotherapy; Prehypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PREHYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 73649137893     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903416436     Document Type: Review

References (38)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223.
2. Lawes CM, Vander HS, Rodgers A. Global burden of bloodpressure - related disease, 2001. Lancet. 2008;371:1513-1518.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure. The JNC7 Report. JAMA. 2003;289:2560-2572.
4. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertension. 2007;25:1105-1187.
5. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al.. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2009 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
6. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
7. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al.. Impact of high-normal pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345: 1291-1297.
8. Chobanian AV. Prehypertension revisited. Hypertension. 2006;48:812-814.
9. Svetkey LP. Management of prehypertension. Hypertension. 2005;45:1056-1061.
10. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al.. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006; 354:1-13.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: 1245-1253.
12. Asia Pacifi c Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Pacific region. J Hypertens. 2003;21:707-716.
13. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al.. Blood pressure stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
14. Carlberg B. Time to lower BP targets for hypertension? Lancet. 2009;374:503-504.
15. ADVANCE Collaborative Group. Effects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial) a randomised controlled trial. Lancet. 2007;370:829-840.
16. Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with noninsulin- dependent diabetes and hypertension. N Eng J Med. 1998;338:645-652.
17. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in a normotensive type 2 diabetic patients on albuminuria. Kidney Int. 2002;61:1088-1097.
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
19. Arguedas JA, Percz MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;3:CD 004349.pub 2.
20. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al.. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet. 2009;374:525-533.
21. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al.. DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
22. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al.. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
23. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med. 1997;157:657-667.
24. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
25. Jackson R. Cardiovascular risk prediction: Are we there yet? Heart. 2008;94:1-3.
26. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365:434-441.
27. Brenner H, Gefeller O, Greenland S. Risk and rate advancement periods as measures of exposure impact on the recurrence of chronic diseases. Epidemiology. 1993;4:229-236.
28. Lackland DT. High blood pressure. A lifetime issue. Hypertension. 2009;54:457-458.
29. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32-38.
30. Vasan RS, Kannel WB. Strategies for cardiovascular risk assessment and prevention over the life course: Progress amid imperfections. Circulation. 2009;120:360-363.
31. European guidelines on cardiovascular disease prevention in clinical practice executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375-2414.
32. Evans JG, Rose G. Hypertension. Br Med Bull. 1971;27: 37-42.
33. Pitt B. Prehypertension. To treat or not to treat: That is the question. Am J Hypertens. 2007;20:492.
34. Pencina MJ, D'Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: The Frammingham Heart Study. Circulation. 2009;119: 3078-3084.
35. Vasan RS. A risk score for risk factors. Rationale and roadmap for preventing hypertension. Hypertension. 2009;54: 454-456.
36. Kivimäki M, Batty GD, Singh-Manoux A, Ferrie JE, Tabak AG, Jokela M, et al.. Validating the Framingham hypertension risk score: Results from the Whitehall II Study. Hypertension. 2009;54:496-501.
37. Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, Levy D, et al.. A risk score for predicting near-term incidence of hypertension: The Framingham Heart Study. Ann Intern Med. 2008;148:102-110.
38. Paynter NP, Cook NR, Everett BM, Sesso HD, Burning JE, Ridker PM. Prediction of incident hypertension risk in women with currently normal blood pressure. Am J Med. 2009;122:464-471.